Warning Against Once-Daily Tenofovir+ddI+3TC, and

On October 14, 2003 Gilead Sciences warned health care professionals against a using ddI plus 3TC plus tenofovir combination, after many patients on that regimen failed to control the virus and developed mutations to the drugs. The "dear doctor" letter, "High Rate of Virologic Failure in Patients with HIV Infection Treated with a Once-Daily Triple NRTI Regimen containing Didanosine, Lamivudine, and Tenofovir" is on the FDA Website,

http://www.fda.gov/medwatch/SAFETY/2003/viread_deardoc.pdf

 

The letter also cautioned against all-NRTI regimens in general, as three other such regimens showed disappointing antiviral results in clinical trials.